Evidence map›Paper›PMID 24523386›Full record

ReviewAmerican journal of physiology. Renal physiology2014

Role of Toll-like receptor-4 in renal graft ischemia-reperfusion injury.

Hailin Zhao, Jessica Santiváñez Perez, Kaizhi Lu, Andrew J T George, Daqing Ma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of physiology. Renal physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 114 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Prolonged dialysis duringFrontiers in immunology · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Toll-like Receptor 4 in Acute Kidney Injury.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Immune response associated with ischemia and reperfusion injury during organ transplantation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Hailin ZhaoAnaesthetics, Pain Medicine, and Intensive Care, Dept. of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK. d.ma@imperial.ac.uk.
Jessica Santiváñez Perez
Kaizhi Lu
Andrew J T George
Daqing Ma
Chelsea and Westminster Hospital · GBArmy Medical University · CNHammersmith Hospital · GBImperial College London · GB

Funding

Medical Research Council
6 · The paper itself

Abstract

Toll-like receptor-4 (TLR-4) has been increasingly recognized as playing a critical role in the pathogenesis of ischemia-reperfusion injury (IRI) of renal grafts. This review provides a detailed overview of the new understanding of the involvement of TLR-4 in ischemia-reperfusion injury of renal grafts and its clinical significance in renal transplantation. TLR-4 not only responds to exogenous microbial motifs but can also recognize molecules which are released by stressed and necrotic cells, as well as degraded products of endogenous macromolecules. Upregulation of TLR-4 is found in tubular epithelial cells, vascular endothelial cells, and infiltrating leukocytes during renal ischemia-reperfusion injury, which is induced by massive release of endogenous damage-associated molecular pattern molecules such as high-mobility group box chromosomal protein 1. Activation of TLR-4 promotes the release of proinflammatory mediators, facilitates leukocyte migration and infiltration, activates the innate and adaptive immune system, and potentiates renal fibrosis. TLR-4 inhibition serves as the target of pharmacological agents, which could attenuate ischemia-reperfusion injury and associated delayed graft function and allograft rejection. There is evidence in the literature showing that targeting TLR-4 could improve long-term transplantation outcomes. Given the pivotal role of TLR-4 in ischemia-reperfusion injury and associated delayed graft function and allograft rejection, inhibition of TLR-4 using pharmacological agents could be beneficial for long-term graft survival.

Indexed as

AnimalsBiglycanGraft RejectionHeat-Shock ProteinsHMGB1 ProteinHumansImmunity, InnateKidney TransplantationKidney Tubular Necrosis, AcuteMyeloid Differentiation Factor 88Polymorphism, GeneticReperfusion InjurySignal TransductionToll-Like Receptor 4BiglycanHeat-Shock ProteinsHMGB1 ProteinMyeloid Differentiation Factor 88TLR4 protein, humanToll-Like Receptor 4delayed graft functionischemia-reperfusion injuryrenal graft failurerenal transplantationToll-like receptor 4

Identifiers

PMID24523386
PMCPMC3989634
OpenAlexW2136392370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.